Apogee Therapeutics Shares Climb on Positive Mid-Stage Trial Results

Dow Jones03-23

By Connor Hart

Shares of Apogee Therapeutics climbed after the company disclosed what it said were positive results from a mid-stage trial of its treatment for moderate-to-severe atopic dermatitis, a chronic skin condition that causes itchy, dry skin and rashes.

The stock rose 17%, to $77.27, shortly after Monday's opening bell. Shares are up 90% over the past year.

The biotechnology company said before the bell that its therapy, zumilokibart, demonstrated durable maintenance of response with both three- and six-month maintenance dosing regimens.

The data marks a significant milestone for the drug, Chief Executive Michael Henderson said, noting its "potential to transform the treatment paradigm as the first six-month dosed therapeutic for patients with AD."

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 23, 2026 09:51 ET (13:51 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621015397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621015397","market":"sg","top_or_hot":-1,"title":"Apogee Therapeutics Shares Climb on Positive Mid-Stage Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> climbed after the company disclosed what it said were positive results from a mid-stage trial of its treatment for moderate-to-severe atopic dermatitis, a chronic skin condition that causes itchy, dry skin and rashes. \n</p>\n<p>\n  The stock rose 17%, to $77.27, shortly after Monday's opening bell. Shares are up 90% over the past year. \n</p>\n<p>\n  The biotechnology company said before the bell that its therapy, zumilokibart, demonstrated durable maintenance of response with both three- and six-month maintenance dosing regimens. \n</p>\n<p>\n  The data marks a significant milestone for the drug, Chief Executive Michael Henderson said, noting its \"potential to transform the treatment paradigm as the first six-month dosed therapeutic for patients with AD.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 23, 2026 09:51 ET (13:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apogee Therapeutics Shares Climb on Positive Mid-Stage Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApogee Therapeutics Shares Climb on Positive Mid-Stage Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-23 21:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> climbed after the company disclosed what it said were positive results from a mid-stage trial of its treatment for moderate-to-severe atopic dermatitis, a chronic skin condition that causes itchy, dry skin and rashes. \n</p>\n<p>\n  The stock rose 17%, to $77.27, shortly after Monday's opening bell. Shares are up 90% over the past year. \n</p>\n<p>\n  The biotechnology company said before the bell that its therapy, zumilokibart, demonstrated durable maintenance of response with both three- and six-month maintenance dosing regimens. \n</p>\n<p>\n  The data marks a significant milestone for the drug, Chief Executive Michael Henderson said, noting its \"potential to transform the treatment paradigm as the first six-month dosed therapeutic for patients with AD.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 23, 2026 09:51 ET (13:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APGE","symbol_name":"Apogee Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2621015397","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621015397","pubTimestamp":1774273860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Apogee Therapeutics climbed after the company disclosed what it said were positive results from a mid-stage trial of its treatment for moderate-to-severe atopic dermatitis, a chronic skin condition that causes itchy, dry skin and rashes.The stock rose 17%, to $77.27, shortly after Monday's opening bell. Shares are up 90% over the past year.The biotechnology company said before the bell that its therapy, zumilokibart, demonstrated durable maintenance of response with both three- and six-month maintenance dosing regimens.The data marks a significant milestone for the drug, Chief Executive Michael Henderson said, noting its \"potential to transform the treatment paradigm as the first six-month dosed therapeutic for patients with AD.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APGE":"Apogee Therapeutics","BK4139":"生物科技","SSI":"Stage Stores Inc","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"Apogee Therapeutics股价因积极的中期试验结果而上涨","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APGE":1.5,"SSI":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Apogee Therapeutics climbed after the company disclosed what it said were positive results from a mid-stage trial of its treatment for moderate-to-severe atopic dermatitis, a chronic skin condition that causes itchy, dry skin and rashes. \n\n\n  The stock rose 17%, to $77.27, shortly after Monday's opening bell. Shares are up 90% over the past year. \n\n\n  The biotechnology company said before the bell that its therapy, zumilokibart, demonstrated durable maintenance of response with both three- and six-month maintenance dosing regimens. \n\n\n  The data marks a significant milestone for the drug, Chief Executive Michael Henderson said, noting its \"potential to transform the treatment paradigm as the first six-month dosed therapeutic for patients with AD.\" \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 09:51 ET (13:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621015397","isCrawlerRequest":true}